Sermorelin (also known as GHRH 1-29) is a research peptide and GHRH analogue. As the shortest fully functional synthetic fragment of GHRH, it is comprised of a 29-amino-acid chain that corresponds to the N-terminal segment of the natural human GHRH.

Mechanism of Action: Sermorelin functions by binding to the growth hormone-releasing hormone receptor (GHRHR) in the anterior pituitary gland. This action mimics the effects of endogenous GHRH, stimulating the pituitary to synthesize and release growth hormone in a pulsatile manner that mirrors the body’s natural physiological rhythms. This is distinct from the direct administration of exogenous human growth hormone (hGH).

Research & Applications: Sermorelin was originally developed for medical use as a diagnostic agent to assess pituitary function and for the treatment of growth hormone deficiency (GHD). In a research context, it is studied for its potential effects on:

• Increasing endogenous growth hormone and IGF-1 levels.

• Promoting the development of lean body mass.

• Supporting lipolysis (fat breakdown).

• Improving sleep quality and recovery.

• Enhancing immune function and bone density.

This product is provided as a lyophilized (freeze-dried) powder in a 10mg vial, intended for reconstitution with a suitable sterile diluent.

Note: This product is intended for research and laboratory use only. It is not for human or veterinary consumption.

Chemical & Physical Data

• Product Name: Sermorelin

• CAS Number: 86168-78-7 (for Sermorelin free base)

  • Note: The acetate salt form, Sermorelin Acetate, is also common and has the CAS Number 114466-38-5.

• Molecular Formula: C₁₄₉H₂₄₆N₄₄O₄₂S

• Molecular Weight: 3357.9 g/mol

• Amino Acid Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂